No Word Yet On Supreme Court’s Plans For Gene Patent Case
This article was originally published in The Gray Sheet
Executive Summary
Association for Molecular Pathology v. Myriad Genetics Inc., a closely watched case on the question of whether human genes are patentable, was noticeably absent from the court’s Feb. 21 list of orders, despite a pending petition for judicial review.
You may also be interested in...
Is That A Diagnostic Method Patent Or A Law Of Nature? Supreme Court Hears Arguments
A case argued before the Supreme Court Dec. 7 offers the justices an opportunity to place stricter limits on the types of claims that diagnostic makers can latch onto for patent protection. But while the justices had many questions on appropriate standards for patent eligibility, few clear answers surfaced.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.